Validation of China Health-Related Outcomes Measures-Cardiovascular Disease
This study aimed to test the psychometric properties of CHROME-CVD. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Xue Li, Rui Li, Feiyi Xiao, Kun Zhao, Xiaolu Zhang, Xinyi Wang, Meichen Li, Ke Guo, Li Wang, Yanan Wu, Harriette Van Spall, Tiantian Gao, Qiang Fu, Feng Xie, CHROME Study Group Tags: Patient-Reported Outcomes Source Type: research
Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
This study analyzes partial orphan cancer drugs’ development, approval, and economics. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Thomas Michaeli, Daniel Tobias Michaeli Tags: Health Policy Analysis Source Type: research
Cost and Utility Estimates per Modified Rankin Scale Score up to 2 Years Post Stroke: Data to Inform Economic Evaluations from a Societal Perspective
This study aims to describe societal cost- and utility estimates per modified Rankin Scale (mRS)-score at different time points within 2 years post stroke. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Florentina M.E. Pinckaers, Janneke P.C. Grutters, Ilse Huijberts, Andrea Gabrio, Hieronymus D. Boogaarts, Alida A. Postma, Robert J. van Oostenbrugge, Wim H. van Zwam, Silvia M.A.A. Evers Tags: Health Policy Analysis Source Type: research
Cost- and Utility Estimates per Modified Rankin Scale-Score up to 2 Years Post-Stroke: Data to Inform Economic Evaluations from a Societal Perspective
This study aims to describe societal cost- and utility estimates per modified Rankin Scale (mRS)-score at different timepoints within two years post-stroke. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Florentina M.E. Pinckaers, Janneke P.C. Grutters, Ilse Huijberts, Andrea Gabrio, Hieronymus D. Boogaarts, Alida A. Postma, Robert J. van Oostenbrugge, Wim H. van Zwam, Silvia M.A.A. Evers Source Type: research
Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
This study analyzes partial orphan cancer drugs’ development, approval, and economics. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Thomas Michaeli, Daniel Tobias Michaeli Source Type: research
Validation of China Health Related Outcomes Measures-cardiovascular disease (CHROME-CVD)
This study aimed to test the psychometric properties of CHROME-CVD. (Source: Value in Health)
Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Xue Li, Rui Li, Feiyi Xiao, Kun Zhao, Xiaolu Zhang, Xinyi Wang, Meichen Li, Ke Guo, Li Wang, Yanan Wu, Harriette Van Spall, Tiantian Gao, Qiang Fu, Feng Xie, CHROME Study Group Source Type: research
A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology
This literature review provides an overview of meaningful change thresholds for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy –General (FACT-G) utilized across hematological cancers and solid tumors (melanoma, lung, bladder, and prostate). (Source: Value in Health)
Source: Value in Health - January 6, 2024 Category: International Medicine & Public Health Authors: Nathan A. Clarke, Julia Braverman, Gill Worthy, James W. Shaw, Bryan Bennett, Devender Dhanda, Kim Cocks Tags: Methodology Source Type: research
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
Healthcare payers often implement coverage policies that restrict the utilization of costly new first-line treatments. Cost-effectiveness analysis can be conducted to inform these decisions by comparing the new treatment with an existing one. However, this approach may overlook important factors such as treatment effect heterogeneity and endogenous treatment selection, policy implementation costs, and diverse patient preferences across multiple treatment options. We aimed to develop a cost-effectiveness analysis framework that considers these real-world factors, facilitating the evaluation of alternative policies related t...
Source: Value in Health - January 5, 2024 Category: International Medicine & Public Health Authors: Boshen Jiao, Josh J. Carlson, Louis P. Garrison, Anirban Basu Tags: Health Policy Analysis Source Type: research
Quantifying the Value of Reduced Health Disparities: Low-Dose Computed Tomography Lung Cancer Screening of High-Risk Individuals Within the United States
This study aimed to measure the value of increasing lung cancer screening rates for high-risk individuals and its impact on health disparities. (Source: Value in Health)
Source: Value in Health - January 5, 2024 Category: International Medicine & Public Health Authors: Jason Shafrin, Jaehong Kim, Moises Marin, Sangeetha Ramsagar, Mark Lloyd Davies, Kyana Stewart, Iftekhar Kalsekar, Anil Vachani Tags: Economic Evaluation Source Type: research
Evaluating Policies of Expanding vs. Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
Healthcare payers often implement coverage policies that restrict the utilization of costly new first-line treatments. Cost-effectiveness analysis (CEA) can be conducted to inform these decisions by comparing the new treatment to an existing one. However, this approach may overlook important factors such as treatment effect heterogeneity and endogenous treatment selection, policy implementation costs, and diverse patient preferences across multiple treatment options. We aimed to develop a comprehensive CEA framework that considers these real-world factors, facilitating the evaluation of alternative policies related to expa...
Source: Value in Health - January 5, 2024 Category: International Medicine & Public Health Authors: Boshen Jiao, Josh J. Carlson, Louis P. Garrison, Anirban Basu Source Type: research
Quantifying The Value of Reduced Health Disparities: Low-Dose CT Lung Cancer Screening of High-Risk Individuals within the US
To measure the value of increasing lung cancer screening rates for high-risk individuals and its impact on health disparities. (Source: Value in Health)
Source: Value in Health - January 5, 2024 Category: International Medicine & Public Health Authors: Jason Shafrin, Jaehong Kim, Moises Marin, Sangeetha Ramsagar, Mark Lloyd Davies, Kyana Stewart, Iftekhar Kalsekar, Anil Vachani Source Type: research
Table of Contents
(Source: Value in Health)
Source: Value in Health - January 1, 2024 Category: International Medicine & Public Health Source Type: research
Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - January 1, 2024 Category: International Medicine & Public Health Source Type: research
Editorial Board
(Source: Value in Health)
Source: Value in Health - January 1, 2024 Category: International Medicine & Public Health Source Type: research
Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany
The objective of this study was to test a new method, called the Online elicitation of Personal Utility Functions (OPUF) approach, to derive an EQ-5D-5L value set from a relatively small sample of patients with rheumatic diseases. (Source: Value in Health)
Source: Value in Health - December 26, 2023 Category: International Medicine & Public Health Authors: Paul Schneider, Katharina Blankart, John Brazier, Ben van Hout, Nancy Devlin Tags: Preference-Based Assessments Source Type: research
